近期,CheckMate-067研究的最新长期随访数据于国际知名肿瘤期刊Journal of Clinical Oncology得以发表。CheckMate-067研究先前的研究数据已经证明纳武利尤单抗单药或联合伊匹木单抗一线治疗无法切除III/IV期黑色素瘤的长期临床获益,此次数据更新报道了6.5年(最短随访时间)随访后的疗效和安全性数据。 研究纳入了945例无法切除III...
近期,CheckMate-067研究的最新长期随访数据于国际知名肿瘤期刊Journal of Clinical Oncology得以发表。CheckMate-067研究先前的研究数据已经证明纳武利尤单抗单药或联合伊匹木单抗一线治疗无法切除III/IV期黑色素瘤的长期临床获益,此次数据更新报...
Frank Stephen Hodi et al,Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067):4-year outcomes of a multicentre, randomised, phase 3 trial,Lancet Oncol. 2018 Nov;19(11):1480-1492 Padmanee Sh...
TRAE不会对生存产生负面影响,因为在每个治疗组中,3/4级TRAE患者的10年MSS率均高于意向治疗人群。 港安健康温馨提示:Nivolumab+Ipilimumab的10年CheckMate067研究结果代表了免疫疗法治疗任何肿瘤类型的3期研究中最长的中位OS,这些结果证明了双重免疫疗法对晚期黑色素瘤患者长期预后的持续益处和影响,凸显了对此类治疗有反应...
CheckMate 067是O药+Y药,O药单用,Y药单用治疗晚期黑色素瘤,多中心,随机,持续四年。 945个病人入组,随机分配三组,O药+Y药(n=314),O药(n=316),Y药(n=315)。 PFS明显延长 O药+Y药:11·5 months (95% CI 8·7−19·3) O药:6·9 months (5·1−10·2) ...
Jedd Wolchok, MD, PhD, chief, melanoma and immunotherapeutics service and Lloyd J. Old Chair for clinical investigation at Memorial Sloan Kettering Cancer Center, discusses the findings of the Phase III CheckMate-067 trial.
A substantial difference in median OS and MSS between patients treated with NIVO + IPI or NIVO was observed in descriptive analyses.Clinical trial information: NCT04540705.NIVO + IPI(n = 314)NIVO(n = 316)IPI(n = 315)Median OS: all pts, mo (95% CI)72.1 (38.2–NR)36.9 (28.2–58.7)...
B08CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL) V Chiarionsileni,R Gonzalez,P Rutkowski,... - 《Journal of Clinical Oncolo...
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data Objectives: Nivolumab is approved as adjuvant therapy for resected stage III/IV melanoma based on the phase 3 CheckMate 238 trial. This analysis compared o... JC Moser,S...
CheckMate 067 是一项多中心、随机、对照、双盲的 III 期研究,入组了年龄 18 岁或以上/组织学确诊的不可切除初治 III 或 IV 期转移性黑色素瘤,ECOG PS 评分 0-1 分,BRAF V600 突变状态已知的患者,患者 1:1:1 随机分配进入纳武单抗+伊...